The trial will look to evaluate and assess R327 as an intravenous dose at faster infusion
rates (15 minutes and 30 minutes) across three cohorts (approximately 12
participants). Plasma and urine will be collected at various time points during and
following dosing to evaluate R327’s concentrations and antibacterial effect in the urine on
various bacterial strains....
If successful, this trial would be indicative of strong therapeutic potential
against UTI infections (simple, complicated & recurring) across all medical
treatment settings - initial stage (medical practice) and advanced stage
(hospital)
First subjects expected to be dosed at Q1 2023
Hoping RCE release interim data , that should light a fire under the SP..NZT
Ann: Recce Selects CMAX for Phase I/II UTI Clinical Trial, page-3
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
57.5¢ |
Change
-0.020(3.36%) |
Mkt cap ! $117.2M | |||
| Open | High | Low | Value | Volume |
| 57.5¢ | 58.0¢ | 57.5¢ | $13.44K | 23.37K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 143 | 57.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 58.0¢ | 4749 | 2 |
View Market Depth
| Last trade - 15.57pm 21/06/2024 (20 minute delay) ? |
| RCE (ASX) Chart |